<DOC>
	<DOCNO>NCT02634801</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy ixekizumab compare fumaric acid ester ( FAE ) methotrexate ( MTX ) participants moderate-to-severe plaque psoriasis naive systemic treatment .</brief_summary>
	<brief_title>A Study Ixekizumab ( LY2439821 ) Participants With Moderate-to-Severe Plaque Psoriasis Naive Systemic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Present moderatetosevere chronic plaque psoriasis base diagnosis chronic psoriasis least 6 month baseline . Participants candidate systemic therapy naive systemic treatment psoriasis . Have ( PASI score &gt; 10 BSA &gt; 10 ) DLQI &gt; 10 screen baseline . Have predominant pattern pustular , erythrodermic , and/or guttate form psoriasis . Have receive systemic nonbiologic psoriasis therapy . Have prior , concurrent , recent use ixekizumab biological psoriasis therapy . Have condition contraindication address local labeling MTX FAE . Presence significant uncontrolled cerebrocardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematologic , neurologic , neuropsychiatric disorder abnormal laboratory value screen . Have severe gastrointestinal disease , oral ulcer , know , active gastrointestinal ulcer . Have serious infection immunocompromised . At screen , participant significant , present , early liver disease , e.g. , explain alcohol consumption hepatic insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fumaderm</keyword>
</DOC>